Cedirogant

DB18951InvestigationalSmall molecule

Cedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis).

Mechanism: Pharmacologically active on Nuclear receptor ROR-gamma
Curator reviewed
Formula / weight: C₂₄H₂₀Cl₃F₃N₂O₃ · 547.78 g/mol (avg)
Also known as: (1-(2,4-dichloro-3-((7-chloro-5-(trifluoromethyl)-1hindol-1-yl)methyl)benzoyl)piperidin-4-yl)acetic acid · 4-piperidineacetic acid, 1-(2,4-dichloro-3-((7-chloro-5-(trifluoromethyl)-1h-indol-1-yl)methyl)benzoyl)-
Code names: ABBV-157

Resolves to

Compound

UNIIX6466M4LVPCAS2055496-11-0ChEMBLCHEMBL5095174

Structure

InChIKeyMNEOHCYSHVKLIC-UHFFFAOYSA-NSMILESOC(=O)CC1CCN(CC1)C(=O)C1=CC=C(Cl)C(CN2C=CC3=CC(=CC(Cl)=C23)C(F)(F)F)=C1Cl

Targets

P51449RORC

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cedirogant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account